1.Young WF, Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007 356 601-610
2. National Institutes of Health NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements 19:1–25 (2002)
3. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. J ClinEndocrinol Metab 84(2), 520 –526 (1999).
4. Wajchenberg BL, Albergaria Pereira PA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer.88 (4),711-36 (2000).
5. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg.25(7),914-26 (2001).
6. Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab.91(11), 2027-37 (2006).
7. Bellantone R, Ferrante A, Boscheriniv M, et al. Role of reoperation in recurrencevof adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery.122(6),1212-8 (1997).
8. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg.25(7), 891-7 (2001).
9. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol.6(8), 719-26 (1999).
10. Pommier RF, Brennan MF. An eleven year experience with adrenocortical carcinoma. Surgery.112(6),963-70 (1992).
11. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol.20(4),941-50 (2002).
12.Terzolo M, Angeli A, Fassnacht M, et al. . Adjuvant mitotane treatment for adrenocortical carcinoma..N Engl J Med.356 (23),2372-80 (2007).
13. Bodie B, Novick AC, Pontes JE, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol. 141(2):257–260 (1989).
14. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 75(10),2587–2591 (1995).
15. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 322(17):1195–2001(1990).
16. Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res.; 33(10),1191–1196 (2000).
17. Bilimoria KY, Shen WT, Elaraj D, et al . Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors.Cancer. 113(11):3130-6 (2008).
18. Cawood T, Hunt P, O'Shea D, Cole D, Soule S.Recommended evaluation of adrenal incidentalomas is costly, has high false positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a re-think? Eur J Endocrinol. 161(4),513-27 (2009).
19. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 25(2), 309-340 (2004).
20. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol . 149(4), 273-285(2003) .
21. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol.169 (1),5-11 (2003).
22. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (‘incidentaloma’). Annals of Internal Medicine. 138(5), 424–429 (2003).
23. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review : Prevalence and Incidence of Endocrine and Metabolic Disorders in the United States: A Comprehensive Review J Clin Endocrinol Metab. 94 (6),1853-1878 (2009).
24. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. PNAS 98(16), 9330–9335 (2001).
25. Latronico AC, Chrousos GP. Extensive Personal Experience: Adrenocortical tumors. J Clin Endocrinol Metab. 82(5), 1317- 1324 (1997).
26. Luton JP, Martinez M, Coste J, Bertherat J. Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur J Endocrinol. 143(1), 111–117 (2000).
27. Abiven G, Coste J, Groussin L et al.Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients. J Clin Endocrinol Metab 91(7), 2650-2655 (2006).
28. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF & Samaan NA Adrenal cortical carcinoma. Cancer. 64(3) ,765–769 (1989).
29. Barzilay JI, Pazianos AG. Adrenocortical Carcinoma. Urol Clin North Am. 16(3),457-68 (1989).
30. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab.87(12):5367-5384 (2002).
31. Lynch HT, Radford B, Lynch JF. SBLA syndrome revisited. Oncology.47(1),75-79 (1990).
32. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 85(2), 637–644 (2000).
33. Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer.47(9), 2153-61 (1981).
34. Libe R, Fratticci A & Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer.14(1), 13–28 (2007).
35. Sandrini R, Ribeiro RC, DeLacerda. Childhood adrenocortical tumors. J Clin Endocrinol Metab 82(7), 2027-2031 (1997).
36. Mendonca BB, Lucon AM, Menezes CAV et al. Clinical, hormonal and pathological findings in a comparative study of adrenal cortical neoplasms in childhood and adulthood. J Urol 154(6), 2004-2009 (1995).
37. Seccia TM, Fassina A, Nussdorfer GG et al. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course. Endocr Relat Cancer. 12 (1), 149–159 (2005).
38. Kurtulmus N, Yarman S, Azizlerli H, Kapran Y.Co-secretion of aldosterone and cortisol by an adrenocortical carcinoma.Horm Res.62(2),67-70 (2004).
39. Abma EM, Kluin PM, Dullaart RP. Malignant aldosterone-producing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism. Neth J Med. 66(6), 252-5 (2008).
40. Nicol MR, Papacleovoulou G, Evans DB, et al. Estrogen biosynthesis in human H295 adrenocortical carcinoma cells. Mol Cell Endocrinol. 300(1-2),115-20 (2009).
41. Hyodo T, Megyesi K, Kahn CR, McLean JP, Friesen HG.Adrenocortical carcinoma and hypoglycemia: evidence for production of nonsuppressible insulin-like activity by the tumor. J Clin Endocrinol Metab. 44(6),1175-84 (1977)
42. Eguchi T, Tokuyama A, Tanaka Y, et al.. Hypoglicemia associated with the production of insuli-like growth factor in adrenocortical carcinoma. Intern Med. 40(8), 759-63 (2001)
43. Sullivan M Boileau M and Hodes CV. Adrenal cortical carcinoma. J Urol 120(6),660-665, (1978),
44. Gröndal S, Eriksson B, Hagenäs L, Werner S, Curstedt T. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma.Acta Endocrinol (Copenh). 122(5),656-63 (1990).
45. Fassnacht M, Allolio B.Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 23(2),273-89 (2009).
46. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrinescompared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 88(2),553-8 (2003).
47. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 287(11),1427-34 ( 2002).
48. Korobkin M, Francis IR, Kloos RT, Dunnick NR. The incidental adrenal mass. Radiol Clin North Am.34(5),1037–1054 (1996).
49. Hamrahian AH, Ioachimescu AG, Remer EM et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocr and Metab 2005; 90: 871–877.
50. Gopan T, Remer E, Hamrahian AH. Evaluating and managing adrenal incidentalomas.Cleve Clin J Med. 73(6),561-8 (2006).
51. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. J Am Coll Surg 202(3) 423-430 (2006).
52. Boland GW, Lee MJ, Gazelle GS et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J of Roentgenol. 171(1), 201–204 (1998).
53.Pena CS, Boland GW, Hahn PF et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology.217(3), 798–802 (2000).
54. Caoili EM, Korobkin M, Francis IR et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology.222(3), 629–633 (2002).
55. Szolar DH, Korobkin M, Reittner P et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 234(2), 479–485 (2005)
56. Park BK, Kim CK, Kim B et al. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology. 243(3), 760–765(2007).
57. Ilias I, Sahdev A, Reznek RH et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 14 (3),587–599 (2007).
58. Kumar R, Chawla M, Fanti S, Zhuang H, Ambrosini V, Alavi A. Role of FDG-PET/PET-CT in evaluation of adrenal lesions in patients with known malignancies J Nucl Med. 48 (Supplement 2), 382P. (2007)
59. Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol. 192(4),956-62 (2009).
60. Murphy JJ, Tawfeeq M, Chang B, Nadel H.Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J Pediatr Surg. 43(12),2186-92 (2008).
61. Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenalmass. Best Pract Res Clin Endocrinol Metab. 19(2),277-92(2005).
62. Caoili EM, Korobkin M, Brown RK et al. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT:quantitative and qualitative evaluation. Acad Radiol. 14(4), 468–475 (2007).
63. Khan T, Sundin A, Juhlin C, Langstrom B, Bergstrom M, Eriksson B. 11C-Metomidate PET imaging of adrenocortical cancer.Eur J Nucl Med Mol Imaging 30(3), 403–410 (2003).
64. Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P. [11C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab .91(4) ,1410–141(2006).
65. Hahner S, Stuermer A, Kreissl M et al. [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J of Clin Endocrinol Metab. 93(6), 2358–2365 (2008).
66. Hennings J, Hellman P, Ahlström H, Sundin A.Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol. 69(2),314-23 (2009).
67. Linos DA. Management approaches to adrenal incidentalomas (adrenalomas): A view from Athens, Greece. Endocrinol Metab Clin North Am 29(1),141–157(2000).
68. Mody MK, Kazerooni EA, Korobkin M. Percutaneous CT-guided biopsy of adrenal masses: immediate and delayed complications. J Comput Assist Tomogr. 19 (3),434–439 (1995).
69. Mazzaglia PJ, Monchik JM.Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. Arch Surg. 144(5),465-70 (2009).
70. Quayle FJ, Spitler JA, Pierce RA, Lairmore TC, Moley JF, Brunt LM.Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery. 142(4),497-502) 2007.
71. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol.13(3),202-206 (1989).
72. Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol.26(12),1612-1619 (2002).
73. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M. Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol. 61(7),787-93 (2008).
74. Goldblum JR, Shannon R, Kaldjian EP et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol. 6(6), 663–668 (1993).
75. Vargas MP, Vargas HI, Kleiner DE et al. Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB. Am J Surg Pathol. 21(5), 556–562 (1997).
76. Terzolo M, Boccuzzi A, Bovio S et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology .57(1), 176–182 (2001).
77. Wachenfeld C, Beuschlein F, Zwermann O et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J Endocrinol. 145(3), 335–341 (2001)
78. Morimoto R, Satoh F, Murakami O et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 55(1), 49–55 (2008).
79. Waldmann J, Feldmann G, Slater EP, et al.Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer. 99(11),1900-7 (2008).
80. Gupta D, Shidham V, Holden J, Layfield L Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl Immunohistochem Mol Morphol. 9(3),215-21 (2001).
81. Khorram-Manesh A, Ahlman H, Jansson S, Nilsson O. N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr Pathol.13(2),99-110 (2002).
82. Tissier F, Louvel A, Grabar S et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol. 150(6), 809–817 (2004).
83. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol. 17(4),345–354 (2006)
84. Gicquel C, Leblond-Francillard M, Bertagna X, Louvel A, Chapuis Y, Luton JP, Girard F, Le Bouc Y.Clonal analysis of human adrenocortical carcinomas and secreting adenomas.Clin Endocrinol (Oxf). 1994 Apr;40(4):465-77.
85. Sidhu S, Marsh DJ, Theodosopoulos G et al. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab.87(7),3467-3474 (2002).
86. Soon PS, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist. 13(5),548-61(2008).
87. Gicquel C, Bertagna X, Gaston V, et al.Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 61(18), 6762-7 (2001).
88. Suh I, Guerrero MA, Kebebew E.Gene-expression profiling of adrenocortical carcinoma. Expert Rev Mol Diagn. 9(4), 343-51 (2009).
89. de Reyniès A, Assié G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 27(7), 1108-15 (2009)
90. Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res.15(2),668-76 (2009).
91. Gicquel C, Bertagna X, Schneid H, et al.Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 78(6):1444-53 (1994).
92. Barlaskar FM, Spalding AC, Heaton JH, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.J Clin Endocrinol Metab. 94(1), 204-12 (2009).
93. Almeida MQ, Fragoso MC, Lotfi CF, et al.. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab. 93(9),3524-31 (2008).
94. Fernandez-Ranvier GG, Weng J, Yeh RF. Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13.World J Surg. 32(5), 873-81 (2008)
95. Fenske W, Völker HU, Adam P, et al.. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 16(3), 919-28 (2009).
96. Mac Farlane DA.Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl. 23(3),155-86 (1958).
97. Hogan TF, Gilchrist KW, Westing DW, Citrin DL. Adrenocortical carcinoma. Cancer.45(11), 2880-3 (1980).
98. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 69(5): 947–951(1994).
99. Soreide JA, Brabrand K & Thoresen SO. Adrenal cortical carcinoma in Norway, 1970–1984. World J Surg 16(4), 663–667 (1992).
100. Schulick RD, Brennan MF. Adrenocortical carcinoma. World J Urol.17(1), 26–34 (1999).
101. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors. Cancer. 115(2),243-50 (2009).
102. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P.The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 119(2),161-70 (1996).
103. Henley DJ, van Heerden JA, Grant CS, Carney JA, Carpenter PC. Adrenal cortical carcinoma—a continuing challenge. Surgery. 94(6),926–931(1983).
104. Assié G, Antoni G, Tissier F, et al.Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 92(1),148-54 (2007).
105. Berruti A, Terzolo M, Sperone P, et al..Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 12(3),657-66 (2005).
106. King DR, Lack EE.Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases.Cancer. 44(1), 239-44 (1979).
107.Chiche L, Dousset B, Kieffer E, Chapuis Y.Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature.Surgery. 139(1), 15-27 (2006).
108. Harrison LE, Gaudin PB, Brennan MF.Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg. 134(2),181-5(1999).
109. Kendrick ML, Lloyd R, Erickson L, et al..Adrenocortical carcinoma: surgical progress or status quo?Arch Surg. 136(5),543-9 (2001).
110. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 112(6),972–979 (1992).
111.Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma: clinical outcome at the end of the 20th century. Cancer. 92(5),1113-21 (2001)
112. Cobb WS, Kercher KW, Sing RF, Heniford BT.Laparoscopic adrenalectomy for malignancy.Am J Surg. 2005 Apr;189(4):405-11.
113. Schteingart DE, Doherty GM, Gauger PG et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 12(3): 667–680 (2005).
114. Bertherat J, Coste J, Bertagna X.Adjuvant mitotane in adrenocortical carcinoma.N Engl J Med.357(12),1256-7 (2007).
115. Rhim H, Dodd 3rd GD, Chintapalli KN et al. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics. 24(1), 41–52(2004).
116. Brown DB. Concepts, considerations, and concerns on the cutting edge of radiofrequency ablation. J Vasc Interv Radiol. 16(5), 597–613 (2005).
117. Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T.Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases.Cancer. 97(3), 554-60 (2003).
118. De Baere T 2006. Local treatment of adrenal cortical carcinoma metastases with interventional radiology techniques. In Adrenal Cancer pp97-106. Ed X Bertagna. Montrouge, France: John Libbey Eurotext.
119.Terzolo M, Berruti A.Adjunctive treatment of adrenocortical carcinoma.Curr Opin Endocrinol Diabetes Obes. 15(3),221-6 (2008).
120. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1, 1dichlorodiphenildi-chloroethane (o,p0-DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 92(6),1385–1392 (2001).
121. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p0-DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 11(10),1281–1287 (2000).
122. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p0-DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol. 31(1),51–57 (1989).
123. Daffara FC, De Francia S, Reimondo G, et al. Biochemical effects of adjuvant mitotane treatment in patients with adrenocortical cancer: results of 1-year follow-up. Proceedings of the 89th Annual Meeting of the Endocrine Society;OR29-5, Toronto, June 2–5 2007.
124. Alexandraki KI, Kaltsas GA, le Roux CW, Fassnacht M, Ajodha S, Christ-Crain M, Akker SA, Drake WM, Edwards R, Allolio B, Grossman AB.Assessment of serum free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf). 2009 May 16 10.1111/j.1365-2265.2009.03631.x
125. Faggiano A, Leboulleux S, Young J, et al. Rapidly progressing high o,p0-DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol. 64(1),110–113 (2006).
126. Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab.91(6),2165–2170 (2006).
127. Terzolo M, Pia A, Berruti A et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 85(6), 2234–2238 (2000).
128.Biller BM, Grossman AB, Stewart PM, et al.Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 93(7),2454-62 (2008).
129. Shalet S, Mukherjee A. Pharmacological treatment of hypercortisolism. Curr Opin Endocrinol Diabetes Obes. 15(3),234-8 (2008).
130. Contreras P, Rojas A, Biagini L et al. Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet. 2(8447), 151–152 (1985).
131. Shaw MA, Nicholls PJ, Smith HJ. Aminoglutethimide and ketoconazole: historical perspectives and future prospects. J Steroid Biochem. 31(1),137-46 (1988)
132. Castinetti F, Fassnacht M, Johanssen S, et al.Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 160(6),1003-10 (2009).
133. Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 115(13), 2816-23 (2009).
134. Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 91(11):4501–4504 (2006).
134. Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. Aug 2 DOI 10.1007/s00280-009-1083-9 (2009).
135. de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz EM, Feige JJ. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J Clin Endocrinol Metab. 85(12),4734-41(2000).
136. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 13(2),535–40(2006).
137. Chacon R, Tossen G, Loria FS, Chacon M. CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol. 23(7),1579–80 (2005).
138. Lee JO, Lee KW, Kim CJ, et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol.39(3),183-5 (2009).
139. Doghman M, Cazareth J, Douguet D, Madoux F, Hodder P, Lalli E. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists.J Clin Endocrinol Metab. 94(6), 2178-83 (2009).